Parasitic eye infections tied to contact lens solution

Article

An inspection conducted by the US Food and Drug Administration determined that a subsidiary of Abbott Park, Ill.-based Abbott Laboratories Inc. failed to disclose multiple reports of a serious parasitic eye infection for more than a year.

An inspection conducted by the US Food and Drug Administration determined that a subsidiary of Abbott Park, Ill.-based Abbott Laboratories Inc. failed to disclose multiple reports of a serious parasitic eye infection for more than a year.

Law firm Schmidt & Clark's managing partner, Michael Schmidt, says the documents reveal the link between Acanthamoeba Keratitis and a popular contact lens solution sold by AMO.

"It confirms our suspicion that AMO knew, or should have known, that there was a significant increase in Acanthamoeba Keratitis cases associated with Complete MoisturePlus," Mr Schmidt says in the article.

The report, obtained under the Freedom of Information Act, revealed that FDA inspectors discovered that AMO failed to disclose at least nine reported cases of the sight-threatening eye infection Acanthamoeba Keratitis among users of the company's Complete MoisturePlus contact lens solution.

According to the report, AMO began receiving complaints of serious corneal infections in February 2006, but those reports were not disclosed until an FDA inspection in late May and early June 2007. The Centres for Disease Control launched its own investigation after receiving increasing reports of the rare infection.

AMO finally recalled Complete MoisturePlus in May 2007 after the release of data showed that users of the product were seven times more likely to be infected with Acanthamoeba Keratitis than those who never used Complete MoisturePlus. The FDA subsequently categorized the withdrawal as a Class I recall, a status reserved for situations where there is a reasonable probability that the recalled product will cause serious health problems or deaths.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.